<code id='CF7A2813FE'></code><style id='CF7A2813FE'></style>
      • <acronym id='CF7A2813FE'></acronym>
      <center id='CF7A2813FE'><center id='CF7A2813FE'><tfoot id='CF7A2813FE'></tfoot></center><abbr id='CF7A2813FE'><dir id='CF7A2813FE'><tfoot id='CF7A2813FE'></tfoot><noframes id='CF7A2813FE'>
      • <optgroup id='CF7A2813FE'><strike id='CF7A2813FE'><sup id='CF7A2813FE'></sup></strike><code id='CF7A2813FE'></code></optgroup>
        5. <b id='CF7A2813FE'><label id='CF7A2813FE'><select id='CF7A2813FE'><dt id='CF7A2813FE'><span id='CF7A2813FE'></span></dt></select></label></b><u id='CF7A2813FE'></u>
          <i id='CF7A2813FE'><strike id='CF7A2813FE'><tt id='CF7A2813FE'><pre id='CF7A2813FE'></pre></tt></strike></i>
           
   
   
   
 

  
           
   
           
    
           
     
          
       Home / explore / leisure time      
           
     
           
      
          leisure time 
           
      
           
      
           
       2025-09-29 04:08:39 
   
      
           
      
           
                        
          leisure time  
          
                                   
                 
                                      author：fashion   
                                        
                                      
                                      Page View：88
                                  
                                    
          
                                   
          Novo Nordisk Denmark
          LISELOTTE SABROE/AFP/Getty Images
          A pill being developed by Danish drugmaker Novo Nordisk may lead to greater weight loss than the obesity therapy Wegovy, the company reported Thursday, citing early data.
          In a Phase 1 trial, participants experienced an average of 13.1% weight loss after 12 weeks of taking the experimental oral medicine amycretin, according to data presented at an investor meeting. In comparison, in an earlier Phase 3 trial of the injectable drug Wegovy, people taking Wegovy lost about 6% of their body weight over the same time period.
          advertisement
          Novo Nordisk has been on a mission to capitalize on its success with Wegovy, which brought in $4.5 billion in sales last year. (The drug is also sold as a diabetes treatment under the name Ozempic. That version of the drug brought in another $14 billion in sales).
          Get unlimited access to award-winning journalism and exclusive events.					
          Subscribe																						Log In															
                      
                              
          
                                 Previous article：

                                
                                          David Liu startup to focus on CRISPR delivery
                                
                            
          Next article：  
                                      
                                          United colonoscopy coverage change 'may cost lives,' doctors say
                                                                    
          

      
           
    


       
       
       
    
     
           
    
           
    
           
   
      
     
           
      
           
       
          Related articles